Liver Diseases  >>  Engerix-B (hepatitis B vaccine recombinant)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Engerix-B (hepatitis B vaccine recombinant) / GSK
NCT00699231: Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Completed
1
30
Europe
HBV-MPL vaccine 208129, Engerix™-B
GlaxoSmithKline
Hepatitis B
12/92
12/92
NCT00354861: A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

Completed
1
48
Europe
hepatitis B antigen (without alum) plus IMP321, CD223, hLAG-3Ig, LAG-3, hepatitis B antigen alone (without alum), Engerix B
Immutep S.A.S., SGS Aster-Cephac (CRO)
Healthy
11/05
02/06
NCT00426712: Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Completed
1
42
US
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, HEPLISAV™, Hepatitis B Vaccine (Recombinant), ENGERIX-B®
Dynavax Technologies Corporation
Hepatitis B
03/08
03/08

Download Options